Shares of analog chip manufacturer Texas Instruments (NASDAQ:TXN)
fell 8.3% in the morning session after China Semiconductor Industry Association issued an emergency directive detailing new methods for verifying the origin of imported chips. According to reports, the location of the wafer fabrication plant would define the origin of imports when tariffs are applied. This meant that companies with manufacturing facilities in the US might be severely affected by the escalating US-China trade tension.
Shares of discount retailer Five Below (NASDAQ:FIVE)
fell 8.7% in the afternoon session after Bloomberg reported the company instructed its vendors to delay the shipment of certain goods to China before their final delivery to the U.S., underscoring the retailer's cautious stance amid escalating trade tensions between the U.S. and China. For investors, while this signaled that the company was closely managing its exposure to tariffs, it also raised the possibility of near-term inventory challenges or missed sales opportunities if delays persisted or demand shifted unexpectedly.
Shares of industrial supplier Fastenal (NASDAQ:FAST) jumped 7% in the afternoon session after the company reported strong first quarter 2025 results which blew past analysts' sales volume expectations. Sales, EBITDA, and EPS were also in line with expectations, which showed the company was executing as expected. Sales growth continued to improve despite broader business activity remaining soft, helped by a bigger base of customers spending more each month. Overall, we think this was a decent quarter.
The U.S. budget deficit has grown to the second-highest six-month gap on record. The red ink deepened to more than $1.3 trillion in the first half of the 2025 fiscal year.
Truist Securities analyst William Stein initiated coverage on MACOM Technology Solutions Holdings with a Buy rating and $125 price target, citing growth in RF and similar components and recent acquisitions boosting financial metrics.
BlackRock delivered a strong first quarter in 2025, topping EPS estimates with robust growth in technology services despite slight revenue underperformance.
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells.
